HAP Trading’s Alaunos Therapeutics TCRT Stock Holding History

HAP Trading’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-247	Closed	-$216K	–	1378
2019 Q2	$216K	Buy	+247	New	+$170K	0.02%	485

Other funds holding TCRT

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

HAP Trading's TCRT Position: Q3 2019 in Review

HAP Trading sold out of Alaunos Therapeutics (TCRT) in Q3 2019, closing a stake of 247 shares — an estimated $216K sold.

HAP Trading first reported a position in TCRT in Q2 2019 and held it in 1 quarter. The position peaked at $216K in Q2 2019. 142 funds tracked by Wall St. Rank hold TCRT as of Q3 2019.

HAP Trading reported no remaining Alaunos Therapeutics position as of Q3 2019 after selling out during the quarter.
HAP Trading sold 247 Alaunos Therapeutics shares in Q3 2019, an estimated $216K.
HAP Trading first reported a position in Alaunos Therapeutics in Q2 2019 and held it in 1 quarter.
HAP Trading's Alaunos Therapeutics position peaked at $216K in Q2 2019.
142 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2019.

Based on HAP Trading's 13F filing for Q3 2019, filed 12 Nov 2019.